PUBLISHER: Renub Research | PRODUCT CODE: 1339009
PUBLISHER: Renub Research | PRODUCT CODE: 1339009
Non-Small Cell Lung Cancer Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis
Non-Small Cell Lung Cancer Market Size is predicted to attain US$ 59.77 Billion in 2030, according to Renub Research. Non-small cell lung cancer is a set of lung cancers that behave and consists of squamous cell carcinoma and adenocarcinoma. Non-small cell lung cancers (NSCLC) remedy alternatives consist of surgical treatment, chemotherapy, radiation remedy, targeted therapy, and immunotherapy. Non-small cell lung cancers accounts for 80%-85% of the overall instances of lung cancer globally and this widespread share of non-small cell lung cancers has pushed the majority of key market leaders to focus on consistent innovation of superior therapeutics and increasing the efficacy of the prevailing therapeutics. This is likewise because of the repute of lung cancers as one of the maximum usually going on cancers within the global and its contribution to a tremendous range of deaths worldwide.
Non-Small Cell Lung Cancer (nsclc) Market will exhibit a CAGR of 11.64% all through forecast duration (2022-2030)
The growing quantity of sufferers laid low with non-small cell lung cancers across the world is one of the key drivers of the increase of the market. This is majorly due to the growing number of humans with bad conduct such as smoking, tobacco & alcohol intake, excessive dose of supplements, and sedentary lifestyle across the world. Additionally, growing pollutants stage inside the air is also one of the predominant factors contributing to the boom within the number of patients. The World Health Organization (WHO) updates from February 2022, 2.2 million patients had been identified with lung cancers in 2020, and non-small cellular lung cancer accounted for nearly 85% of the proportion of all lung cancers sufferers. Thus, the availability of a massive affected person base and a addition growing range of non-small cell lung cancer patients resulted within the excessive demand for remedy to deal with the sufferers.
The non-small cell lung cancers market boom is majorly driven via boom in price of tobacco consumption more by younger group, extreme air pollution, and dangerous way of life. Exposure to air containing lines of metals consisting of asbestos, arsenic, and others, are predominant motives of adenocarcinoma. Thus, increase in variety of humans smoking and following unhealthy way of life are some of the important factors causing NSCLC. Also, among all lung cancer cases, majority of patients are affected by non-small cell lung cancer. For example, in keeping with National Centre for Biotechnology Information (NCBI), 85% of cases are non-small cell lung cancers instances. In addition, boom in studies and improvement sports by using key players including Roche and Eli Lilly propels the growth of the market. Rise in incidence of Lung cancer cases, which caused rise in demand for non-small cell lung cancer treatment market. The Non-Small Cell Lung Cancer market turned into worth US$ 24.77 Billion in 2022.
Adenocarcinoma holds the essential market share in the non-small cell lung cancers (NSCLC) industry
By Type, Non-Small Cell Lung Cancer market is divided into Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma. In the realm of non-small cell lung cancers, Adenocarcinoma stands because the essential subtype, boasting the important market share. This unique form of lung cancer encompasses diverse traits and genetic profiles, influencing its incidence and impact. Its prominence may be attributed to factors inclusive of its extraordinary histological functions, various molecular alterations, and ranging responses to targeted treatment plans. The massive research and advancements dedicated to understanding Adenocarcinoma's complexities have led to extra correct diagnoses, tailor-made remedy strategies, and advanced affected person results. As the primary participant within the non-small cell lung cancers panorama, Adenocarcinoma's dominance underscores its significance in shaping the trajectory of clinical improvements and healing procedures inside the field.
Chemotherapy is emerging as the fastest-developing sales in the non-small cell lung cancer market
By Treatment, Non-Small Cell Lung Cancer market is split into Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy Drugs. Chemotherapy has emerged due to the fastest growing approach within the non-small cell lung cancers industry. Its dynamic role in treating this cancers subtype is attributed to its capability to target swiftly dividing cells and prevent their boom. Chemotherapy is hired at diverse levels of non-small cell lung cancer, which includes neoadjuvant, adjuvant, and palliative settings. The development of novel agents, aggregate remedies, and customized remedy regimens has propelled chemotherapy effectiveness at the same time as minimizing aspect consequences. This growth is in addition fueled by means of ongoing studies into optimizing drug shipping, minimizing resistance, and enhancing affected person quality of lifestyles. As a cornerstone of non-small cell lung cancer remedy, chemotherapy rapid expansion indicates its pivotal contribution to enhancing results and reshaping the landscape of lung cancer control.
Ongoing studies and evolving Kinase Inhibitors solidify their dominant position in advancing non-small cell lung cancer treatment Market
By Drug Class, Non-Small Cell Lung Cancer market is split into Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites and PD-1/ PD-L1 Inhibitor. Kinase inhibitors dominate the non-small cell lung cancers enterprise with the largest market share. These targeted cures have revolutionized cancer remedy by using that specializes in unique molecular pathways that drive tumor boom. By blockading the pastime of kinases, which are enzymes involved in cell signaling, these inhibitors successfully halt cancers cellular proliferation and progression. Their fulfillment lies of their precision, as they selectively goal cancerous cells whilst sparing wholesome ones, minimizing aspect consequences. The continuous improvement of kinase inhibitors, pushed by way of improvements in precision medication and genomic profiling, has propelled their sizeable adoption. Their efficacy, coupled with customized treatment techniques, has reshaped the landscape of non-small cell lung cancer therapy, presenting patients progressed consequences and enhanced exceptional of existence.
Specialty hospitals are experiencing the quickest growth within the realm of non-small cell lung cancers remedy
By End User, Non-Small Cell Lung Cancer market is divided into Hospitals, Specialty Hospitals Clinics and Others. The realm of non-small cell lung cancers treatment is witnessing a speedy growth pushed through the splendid boom of forte hospitals. These healthcare facilities, committed to imparting targeted and superior care, have emerged as pivotal players within the fight in opposition to the disease. Their knowledge, present day technologies, and multidisciplinary method permit them to offer tailored and comprehensive treatment plans to sufferers.
Specialty hospitals cater particularly to the complicated wishes of lung cancers sufferers, supplying conducive surroundings for superior diagnostics, targeted healing procedures, surgical interventions, and post-treatment help. This surge in specialty health facility improvement underscores the dedication to enhancing affected person outcomes and reflects the dynamic landscape of lung cancers care, in which specialized institutions are at the leading edge of revolutionary remedies and more suitable patient reviews.
United States continues to set the tempo in shaping the panorama of non-small cell lung cancer treatment and affected person care on a global scale
By Country, Non-Small Cell Lung Cancer market is divided into United States, Canada, Germany, United Kingdom, France, Italy, Netherlands, Spain, China, South Korea, Japan, India, Indonesia, Malaysia, Australia, Argentina, Brazil, Mexico, Colombia, Saudi Arabia, UAE, Israel, South Africa, and Rest of World. The United States commands the highest proportion within the non-small cell lung cancers treatment market. Renowned for its superior healthcare infrastructure, current research, and a robust pharmaceutical industry, the U.S. Stands as a pivotal hub for the development and implementation of progressive cures.
A multitude of things make contributions to its dominance, together with an excessive incidence of lung cancer instances, full-size investments in cancers research, and a proactive regulatory environment that allows drug approvals and scientific trials. The presence of global-elegance scientific establishments and a collaborative atmosphere of healthcare specialists similarly bolster the USA of a'sprominence in non-small cell lung cancers treatment market.
Major Players
The non-small cell lung cancer market is fragmented and consists of several main players those are Bayar Healthcare, Eli Lilly, BiogenInc, Merck $ Co, AbbVieInc, AstraZeneca, Novartis, Pfizer Inc, Avid BioservicesInc, Blueprint Medicines Company and AstellasPharma.
Renub Research latest report "Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast By Type (Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma), Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy Drugs), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites and PD-1/ PD-L1 Inhibitor), End User (Hospitals, Specialty Hospitals Clinics and Others), Country (United States, Canada, Germany, United Kingdom, France, Italy, Netherlands, Spain, China, South Korea, Japan, India, Indonesia, Malaysia, Australia, Argentina, Brazil, Mexico, Colombia, Saudi Arabia, UAE, Israel, South Africa, and Rest of World), Companies (Bayar Healthcare, Eli Lilly, BiogenInc, Merck $ Co, AbbVieInc, AstraZeneca, Novartis, Pfizer Inc, Avid BioservicesInc, Blueprint Medicines Company and AstellasPharma)" provides a detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) Industry.
Type - Market has been covered from 3 viewpoints:
- 1. Adenocarcinoma
- 2. Squamous Cell Carcinoma
- 3. Large Cell Carcinoma
Treatment - Market has been covered from 5 viewpoints:
- 1. Chemotherapy
- 2. Immunotherapy
- 3. Radiation Therapy
- 4. Surgery
- 5. Targeted Therapy Drugs
Drug Class - Market has been covered from 6 viewpoints:
- 1. Angiogenesis Inhibitor
- 2. Epidermal Growth Factor Receptor Blocker
- 3. Kinase Inhibitor
- 4. Microtubule Stabilizer
- 5. Folate Antimetabolites
- 6. PD-1/ PD-L1 Inhibitor
End User - Market has been covered from 4 viewpoints:
- 1. Hospitals
- 2. Specialty Hospitals
- 3. Clinics
- 4. Others
Country - Market has been covered from 24 viewpoints:
- 1. North America
- 1.1. United States
- 1.2. Canada
- 2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Netherlands
- 2.6. Spain
- 3. Asia Pacific
- 3.1. China
- 3.2. South Korea
- 3.3. Japan
- 3.4. India
- 3.5. Indonesia
- 3.6. Malaysia
- 3.7. Australia
- 4. Latin America
- 4.1. Argentina
- 4.2. Brazil
- 4.3. Mexico
- 4.4. Colombia
- 5. Middle East & Africa
- 5.1. Saudi Arabia
- 5.2. UAE
- 5.3. Israel
- 5.4. South Africa
- 6. Rest of World
Company Insights:
- Overview
- Recent Development
- Revenue
Key Players:
- 1. Bayar Healthcare
- 2. Eli Lilly
- 3. BiogenInc
- 4. Merck $ Co
- 5. AbbVieInc
- 6. AstraZeneca
- 7. Novartis
- 8. Pfizer Inc
- 9. Avid Bioservices, Inc
- 10. Blueprint Medicines Company
- 11. AstellasPharma
Table of Contents
1. Introduction
2. Research& Methodology
3. Executive Summary
4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
5. Non-Small Cell Lung Cancer Treatment (NSCLC) Market
6. Market Share - Non-Small Cell Lung Cancer Treatment (NSCLC)
- 6.1 By Type
- 6.2 By Treatment
- 6.3 By Drug Class
- 6.4 By End User
- 6.5 By Country
7. Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
- 7.1 Adenocarcinoma
- 7.2 Squamous Cell Carcinoma
- 7.3 Large Cell Carcinoma
8. Treatment - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
- 8.1 Chemotherapy
- 8.2 Immunotherapy
- 8.3 Radiation Therapy
- 8.4 Surgery
- 8.5 Targeted Therapy Drugs
9. Drug Class - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
- 9.1 Angiogenesis Inhibitor
- 9.2 Epidermal Growth Factor Receptor Blocker
- 9.3 Kinase Inhibitor
- 9.4 Microtubule Stabilizer
- 9.5 Folate Antimetabolites
- 9.6 PD-1/ PD-L1 Inhibitor
10. End User - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
- 10.1 Hospitals
- 10.2 Specialty Hospitals
- 10.3 Clinics
- 10.4 Others
11. Country - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
- 11.1 North America
- 11.1.1 United States
- 11.1.2 Canada
- 11.2 Europe
- 11.2.1 Germany
- 11.2.2 United Kingdom
- 11.2.3 France
- 11.2.4 Italy
- 11.2.5 Netherlands
- 11.2.6 Spain
- 11.3 Asia Pacific
- 11.3.1 China
- 11.3.2 South Korea
- 11.3.3 Japan
- 11.3.4 India
- 11.3.5 Indonesia
- 11.3.6 Malaysia
- 11.3.7 Australia
- 11.4 Latin America
- 11.4.1 Argentina
- 11.4.2 Brazil
- 11.4.3 Mexico
- 11.4.4 Colombia
- 11.5 Middle East & Africa
- 11.5.1 Saudi Arabia
- 11.5.2 UAE
- 11.5.3 Israel
- 11.5.4 South Africa
- 11.6 Rest of World
12. Porters Five Forces - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market
- 12.1 Bargaining Power of Buyers
- 12.2 Bargaining Power of Suppliers
- 12.3 Degree of Rivalry
- 12.4 Threat of New Entrants
- 12.5 Threat of Substitutes
13. SWOT Analysis - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market
- 13.1 Strength
- 13.2 Weakness
- 13.3 Opportunity
- 13.4 Threat
14. Key Players
- 14.1 Bayer Healthcare
- 14.1.1 Overview
- 14.1.2 Recent Development
- 14.1.3 SWOT Analysis
- 14.1.4 Revenue
- 14.2 Eli Lilly and Company
- 14.2.1 Overview
- 14.2.2 Recent Development
- 14.2.3 SWOT Analysis
- 14.2.4 Revenue
- 14.3 Biogeninc
- 14.3.1 Overview
- 14.3.2 Recent Development
- 14.3.3 SWOT Analysis
- 14.3.4 Revenue
- 14.4 Merck & co Inc.
- 14.4.1 Overview
- 14.4.2 Recent Development
- 14.4.3 SWOT Analysis
- 14.4.4 Revenue
- 14.5 AbbVie Inc.
- 14.5.1 Overview
- 14.5.2 Recent Development
- 14.5.3 SWOT Analysis
- 14.5.4 Revenue
- 14.6 AstraZeneca
- 14.6.1 Overview
- 14.6.2 Recent Development
- 14.6.3 SWOT Analysis
- 14.6.4 Revenue
- 14.7 Novartis
- 14.7.1 Overview
- 14.7.2 Recent Development
- 14.7.3 SWOT Analysis
- 14.7.4 Revenue
- 14.8 Pfizer Inc.
- 14.8.1 Overview
- 14.8.2 Recent Development
- 14.8.3 SWOT Analysis
- 14.8.4 Revenue
- 14.9 Avid Bioservices, Inc.
- 14.9.1 Overview
- 14.9.2 Recent Development
- 14.9.3 SWOT Analysis
- 14.9.4 Revenue
- 14.10 Blueprint Medicines Corp
- 14.10.1 Overview
- 14.10.2 Recent Development
- 14.10.3 SWOT Analysis
- 14.10.4 Revenue
- 14.11 AstellasPharma
- 14.11.1 Overview
- 14.11.2 Recent Development
- 14.11.3 SWOT Analysis
- 14.11.4 Revenue
List of Figures
- Figure-01: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2018 - 2022
- Figure-02: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2023 - 2030
- Figure-03: Type - Adenocarcinoma Market (Billion US$), 2018 - 2022
- Figure-04: Type - Forecast for Adenocarcinoma Market (Billion US$), 2023 - 2030
- Figure-05: Type - Squamous Cell Carcinoma Market (Billion US$), 2018 - 2022
- Figure-06: Type - Forecast for Squamous Cell Carcinoma Market (Billion US$), 2023 - 2030
- Figure-07: Type - Large Cell Carcinoma Market (Billion US$), 2018 - 2022
- Figure-08: Type - Forecast for Large Cell Carcinoma Market (Billion US$), 2023 - 2030
- Figure-09: Treatment - Chemotherapy Market (Billion US$), 2018 - 2022
- Figure-10: Treatment - Forecast for Chemotherapy Market (Billion US$), 2023 - 2030
- Figure-11: Treatment - Immunotherapy Market (Billion US$), 2018 - 2022
- Figure-12: Treatment - Forecast for Immunotherapy Market (Billion US$), 2023 - 2030
- Figure-13: Treatment - Radiation Therapy Market (Billion US$), 2018 - 2022
- Figure-14: Treatment - Forecast for Radiation Therapy Market (Billion US$), 2023 - 2030
- Figure-15: Treatment - Surgery Market (Billion US$), 2018 - 2022
- Figure-16: Treatment - Forecast for Surgery Market (Billion US$), 2023 - 2030
- Figure-17: Treatment - Targeted Therapy Drugs Market (Billion US$), 2018 - 2022
- Figure-18: Treatment - Forecast for Targeted Therapy Drugs Market (Billion US$), 2023 - 2030
- Figure-19: Drug Class - Angiogenesis Inhibitor Market (Billion US$), 2018 - 2022
- Figure-20: Drug Class - Forecast for Angiogenesis Inhibitor Market (Billion US$), 2023 - 2030
- Figure-21: Drug Class - Epidermal Growth Factor Receptor Blocker Market (Billion US$), 2018 - 2022
- Figure-22: Drug Class - Forecast for Epidermal Growth Factor Receptor Blocker Market (Billion US$), 2023 - 2030
- Figure-23: Drug Class - Kinase Inhibitor Market (Billion US$), 2018 - 2022
- Figure-24: Drug Class - Forecast for Kinase Inhibitor Market (Billion US$), 2023 - 2030
- Figure-25: Drug Class - Microtubule Stabilizer Market (Billion US$), 2018 - 2022
- Figure-26: Drug Class - Forecast for Microtubule Stabilizer Market (Billion US$), 2023 - 2030
- Figure-27: Drug Class - Folate Antimetabolites Market (Billion US$), 2018 - 2022
- Figure-28: Drug Class - Forecast for Folate Antimetabolites Market (Billion US$), 2023 - 2030
- Figure-29: Drug Class - PD-1/ PD-L1 Inhibitor Market (Billion US$), 2018 - 2022
- Figure-30: Drug Class - Forecast for PD-1/ PD-L1 Inhibitor Market (Billion US$), 2023 - 2030
- Figure-31: End User - Hospitals Market (Billion US$), 2018 - 2022
- Figure-32: End User - Forecast for Hospitals Market (Billion US$), 2023 - 2030
- Figure-33: End User - Specialty Hospitals Market (Billion US$), 2018 - 2022
- Figure-34: End User - Forecast for Specialty Hospitals Market (Billion US$), 2023 - 2030
- Figure-35: End User - Clinics Market (Billion US$), 2018 - 2022
- Figure-36: End User - Forecast for Clinics Market (Billion US$), 2023 - 2030
- Figure-37: End User - Others Market (Billion US$), 2018 - 2022
- Figure-38: End User - Forecast for Others Market (Billion US$), 2023 - 2030
- Figure-39: United States - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-40: United States - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-41: Canada - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-42: Canada - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-43: Germany - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-44: Germany - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-45: United Kingdom - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-46: United Kingdom - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-47: France - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-48: France - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-49: Italy - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-50: Italy - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-51: Netherlands - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-52: Netherlands - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-53: Spain - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-54: Spain - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-55: China - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-56: China - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-57: South Korea - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-58: South Korea - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-59: Japan - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-60: Japan - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-61: India - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-62: India - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-63: Indonesia - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-64: Indonesia - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-65: Malaysia - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-66: Malaysia - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-67: Australia - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-68: Australia - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-69: Argentina - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-70: Argentina - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-71: Brazil - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-72: Brazil - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-73: Mexico - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-74: Mexico - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-75: Colombia - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-76: Colombia - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-77: Saudi Arabia - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-78: Saudi Arabia - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-79: UAE - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-80: UAE - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-81: Israel - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-82: Israel - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-83: South Africa - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-84: South Africa - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-85: Rest of World - Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2018 - 2022
- Figure-86: Rest of World - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) (Million US$), 2023 - 2030
- Figure-87: Bayer Healthcare - Global Revenue (Billion US$), 2018 - 2022
- Figure-88: Bayer Healthcare - Forecast for Global Revenue (Billion US$), 2023 - 2030
- Figure-89: Eli Lilly and Company - Global Revenue (Billion US$), 2018 - 2022
- Figure-90: Eli Lilly and Company - Forecast for Global Revenue (Billion US$), 2023 - 2030
- Figure-91: Biogeninc - Global Revenue (Billion US$), 2018 - 2022
- Figure-92: Biogeninc - Forecast for Global Revenue (Billion US$), 2023 - 2030
- Figure-93: Merck & co inc - Global Revenue (Billion US$), 2018 - 2022
- Figure-94: Merck & co inc - Forecast for Global Revenue (Billion US$), 2023 - 2030
- Figure-95: AbbVie Inc. - Global Revenue (Billion US$), 2018 - 2022
- Figure-96: AbbVie Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2030
- Figure-97: AstraZeneca - Global Revenue (Billion US$), 2018 - 2022
- Figure-98: AstraZeneca - Forecast for Global Revenue (Billion US$), 2023 - 2030
- Figure-99: Novartis - Global Revenue (Billion US$), 2018 - 2022
- Figure-100: Novartis - Forecast for Global Revenue (Billion US$), 2023 - 2030
- Figure-101: Pfizer Inc. - Global Revenue (Billion US$), 2018 - 2022
- Figure-102: Pfizer Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2030
- Figure-103: Avid Bioservices, Inc. - Global Revenue (Million US$), 2018 - 2022
- Figure-104: Avid Bioservices, Inc. - Forecast for Global Revenue (Million US$), 2023 - 2030
- Figure-105: Blueprint Medicines Corp - Global Revenue (Million US$), 2018 - 2022
- Figure-106: Blueprint Medicines Corp - Forecast for Global Revenue (Million US$), 2023 - 2030
- Figure-107: AstellasPharma - Global Revenue (Billion US$), 2018 - 2022
- Figure-108: AstellasPharma - Forecast for Global Revenue (Billion US$), 2023 - 2030
List of Tables
- Table-01: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type (Percent), 2018 - 2022
- Table-02: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type (Percent), 2023 - 2030
- Table-03: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment (Percent), 2018 - 2022
- Table-04: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment (Percent), 2023 - 2030
- Table-05: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2018 - 2022
- Table-06: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2023 - 2030
- Table-07: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2018 - 2022
- Table-08: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2023 - 2030
- Table-09: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Countries (Percent), 2018 - 2022
- Table-10: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Countries (Percent), 2023 - 2030
